[39], where loss of TET2 was shown to increase stem‐cell self‐renewal in vivo, ultimately leading to the development of myeloproliferative disorders accompanied by splenomegaly, extramedullary hematopoiesis, and monocytosis. Here, TET2 is linked to myeloproliferative disorder.